Acute Myeloid Leukemia Clinical Trials in Nashville, Tennessee

12 studies are recruiting for acute myeloid leukemia in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

    This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and …

    Stage
    Phase 3
    Ages
    0 to 21
    Site
    The Children's Hospital at TriStar Centennial, Nashville, Tennessee
    Locations
    206 in total
    Run by
    Children's Oncology Group
  2. A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

    Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse events and how pivekimab sunirine moves through the body in pediatric participants with relapsed or ref…

    Stage
    Phase 1
    Ages
    0 to 17
    Site
    Tristar Centennial Medical Center /ID# 275831, Nashville, Tennessee
    Locations
    13 in total
    Run by
    AbbVie
  3. Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

    This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound found in fruits and vegetables. Xylitol has been shown to limit …

    Stage
    Phase 3
    Ages
    1 to 25
    Site
    The Children's Hospital at TriStar Centennial, Nashville, Tennessee
    Locations
    39 in total
    Run by
    Children's Oncology Group
  4. CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

    This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.

    Stage
    Phase 1
    Ages
    18 to 85
    Site
    Sarah Cannon Research Insitute, Nashville, Tennessee
    Locations
    5 in total
    Run by
    CERo Therapeutics Holdings, Inc.
  5. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

    Stage
    Phase 1
    Ages
    Up to 22
    Site
    The Children's Hospital at TriStar Centennial, Nashville, Tennessee
    Locations
    184 in total
    Run by
    PedAL BCU, LLC
  6. Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

    A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or…

    Stage
    Phase 3
    Ages
    0 to 21
    Site
    Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
    Locations
    90 in total
    Run by
    PedAL BCU, LLC
  7. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Vanderbilt University Medical Center, Nashville, Tennessee
    Locations
    45 in total
    Run by
    Kura Oncology, Inc.
  8. Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

    This phase I trial tests the safety, side effects, and best dose of eltanexor in combination with venetoclax for the treatment of patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to pre…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
    Locations
    2 in total
    Run by
    Vanderbilt-Ingram Cancer Center
  9. A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

    Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (o…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Vanderbilt University Medical Center, Nashville, Tennessee
    Locations
    71 in total
    Run by
    Taiho Oncology, Inc.
  10. A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

    Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in pat…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    TriStar Bone Marrow Transplant, Nashville, Tennessee
    Locations
    44 in total
    Run by
    Kura Oncology, Inc.
  11. A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

    This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Vanderbilt University, Nashville, Tennessee
    Locations
    7 in total
    Run by
    Solu Therapeutics, Inc
  12. Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

    Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

    Stage
    Phase 1
    Ages
    18 and older
    Site
    TriStar Bone Marrow Transplant, Nashville, Tennessee
    Locations
    5 in total
    Run by
    Vincerx Pharma, Inc.

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.